Sudarshan Pharma Industries is under due diligence for acquiring a 9.50% stake in MedTherapy Biotechnology. This includes a 1.50% stake from its promoters. The acquisition aims to enhance its US market presence, with completion expected by March 2027.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.